Introduction
The global burden of tuberculosis is unacceptably high (panel 1) 1 and multidrug-resistant (MDR) tuberculosis is now a major health challenge worldwide. Of notifi ed cases of pulmonary tuberculosis in 2011, an estimated 310 000 new cases were MDR, defi ned by active infection with Mycobacterium tuberculosis that is resistant to isoniazid and rifampicin. 1 To eliminate tuberculosis as a public health problem by 2050, incidence will have to fall by an average of 16% per year for the next 40 years.
• The Xpert MTB/RIF assay is a landmark development in tuberculosis diagnostics and yet it does not fulfi l requirements as a point-of-care assay • One Xpert MTB/RIF test on sputum detects 90% of pulmonary tuberculosis (99% of smear-positive disease and about 75% of smear-negative disease) • High sensitivity of Xpert MTB/RIF for rifampicin resistance is accompanied by some false-positive results (which might be reduced by the new G4 version of the assay) and confi rmatory drug sensitivity testing is needed • Despite substantial price discounting and relative simplicity of use, implementation of the Xpert MTB/RIF assay is hindered by several factors • Studies of clinical and programmatic eff ects and associated cost-eff ectiveness of the Xpert MTB/RIF assay are needed • Greater funding for research and development for a simple, low-cost, accurate point-of-care assay is needed 
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These tests do not have suffi cient sensitivity or specifi city, are too slow, or are not available at the periphery of the health system where patients fi rst seek care.
Opportunities to intervene early in the disease are therefore lost. Global capacity for drug susceptibility testing (DST) is inadequate and only 9% of the estimated 630 000 prevalent cases of MDR tuberculosis worldwide in 2011 were diagnosed and notifi ed.
1,3
For the past 5 years, the development of diagnostics for tuberculosis has progressed rapidly (fi gure). 4 Old technologies have been reviewed and improved and new technologies have been developed, evaluated, and implemented. With a growing evidence base, WHO issued ten policy statements between 2007 and 2012 about tuberculosis diagnosis and diag nostic methods, which shows the progress that has been made. These policy statements address improvements in sputum smear microscopy, 5-8 use of commercial and non-commerical culture-based systems for diagnosis and DST, 9,10 and implementation of line-probe assays 11 for rapid molecular diagnosis of drug resistance. Negative recommendations were issued about the use of serodiagnostic tests and interferon-gamma release assays for diagnosis of tuberculosis or latent M tuberculosis infection in lowincome and middle-income countries.
12,13 After initial endorsement in December, 2010, WHO issued a policy statement in 2011, on the Xpert MTB/RIF automated molecular assay for rapid diagnosis of tuberculosis and detection of rifampicin resistance.
14 Specifi cally, the assay was strongly recommended for use as the initial diagnostic test in individuals suspected of having MDR or HIV-associated tuberculosis. 15 The assay was also conditionally recommended as a follow-on test to microscopy in settings where MDR tuberculosis and HIV-associated tuberculosis are less of a concern.
The development of the Xpert MTB/RIF assay is a landmark event in tuberculosis research, and this article summarises what is known about this assay, its assessment in diff erent settings, and its implementation. Despite many compelling attributes of this new diagnostic test, the Xpert MTB/RIF assay is by no means the ideal test. We discuss the challenges associated with its use in resource-limited settings and review other important developments and future prospects within the diag nostics developmental pipeline.
Development of the Xpert MTB/RIF assay
The GeneXpert diagnostic system was originally developed by Cepheid (Sunnyvale, CA, USA) for rapid detection of anthrax, 16 and was deployed for this purpose by the US Postal Service to permit rapid detection of mail contamination in sorting offi ces. It is a self-contained, ( Rifampicin resistance is particularly amenable to rapid molecular detection because 95% of all rifampicinresistant M tuberculosis strains contain mutations localised within the 81 bp core region of the bacterial RNA polymerase β subunit (rpoB) gene, which encodes the active site of the enzyme. 18 Moreover, mutations that occur in this region are highly predictive of rifampicin resistance 18, 19 and the core region is fl anked by M tuberculosis complex-specifi c DNA sequences. Thus, M tuberculosis and rifampicin resistance can be tested simultaneously by targeting one amplicon generated with PCR technology. Moreover, rifampicin resistance is strongly, although not invariably, indicative of MDR tuberculosis.
The Xpert MTB/RIF assay uses molecular beacon technology 20, 21 to detect DNA sequences amplifi ed in a heminested real-time-PCR assay. The assay uses singleuse plastic cartridges with several chambers that are preloaded with liquid buff ers and lyophilised reagent beads necessary for sample processing, DNA extraction, and PCR. 22, 23 Sample reagent included in the assay is designed to reduce the viability of M tuberculosis in sputum and reduce the biohazard risk. 24 Subsequent processing is fully automated and results are available within 2 h with less than 20 min of hands-on time.
Preclinical laboratory-based assessment
A thorough preclinical assessment of analytic performance and biosafety of the Xpert MTB/RIF assay was done.
17 By spiking defi ned numbers of M tuberculosis bacilli into clinical sputum samples from patients without tuberculosis, the limit of detection (95% reliability for detection) of the assay was 131 colony forming units (cfu)/ mL (95% CI 106-176) of sputum. 22 This result contrasts with the limit of detection of automated mycobacterial liquid culture, which is about 10-50 cfu/mL, and with that of smear microscopy, which is about 10 000 cfu/mL. 25 Thus, the Xpert MTB/RIF assay has a sensitivity that is roughly two orders of magnitude greater than that of smear microscopy, is similar to solid culture, but is not quite as sensitive as liquid culture. The assay correctly identifi ed genomic DNA from 79 phylogenetically and geographically diverse strains of M tuberculosis 23 and no cross-reactivity occurred with a wide range of nontuberculous mycobacteria or other organisms known to infect the respiratory tract. 22, 23 Further experiments showed that false-positive reactions due to laboratory cross-contamination with amplicons from the GenoType MTBDRplus assay (Hain Lifescience, Nehren, Germany) was very unlikely. 23 Genomic DNA from several rifampicin-susceptible and rifampicin-resistant M tuberculosis isolates with diverse rpoB mutations were tested, and excellent accuracy for rifampicin resistance was reported. 22, 23 Further experiments were done in which DNA from resistant and susceptible strains were mixed in varying ratios to assess how this aff ected detection of rifampicin resistance. 23 To enable detection, 65-100% of the DNA from the rifampicin-resistant isolate had to be present, depending on the mutation. 23 Overall, this fi nding suggests that in patients with mixed infections, the Xpert MTB/RIF assay might only detect the resistant strain if this strain is predominant. Moreover, subsequent selection of resistant strains during the course of standard tuber culosis treatment might lead to an apparent switch from a susceptible to a resistant phenotype when baseline testing is compared with repeat testing during treatment.
To assess biosafety requirements for the Xpert MTB/RIF assay, bioaerosol generation and bacterial viability studies were done. The viability of M tuberculosis was reduced by more than 8 logs within 15 min of incubation of sputum in sample reagent. 22 Viable bioaerosols were not gen erated during the manual sputum processing with sample reagent or during automated processing with the Xpert MTB/RIF assay, whereas infectious bioaerosols were generated during routine preparation of smears. 24 These data therefore suggest that the Xpert MTB/RIF assay poses a substantially smaller biohazard risk compared with direct smear microscopy and, given adequate room ventilation, might reasonably be done without the need for special equipment such as biosafety cabinets, which are absent in most resource-limited settings.
Diagnostic accuracy of the Xpert MTB/RIF assay for pulmonary tuberculosis
Many studies in both high-income and resourcelimited settings of the diagnostic accuracy of the Xpert MTB/RIF assay for pulmonary tuberculosis have been published.
17, 26 The multicountry assessment done by the Foundation for Innovative and New Diagnostics (FIND), published in 2010, 27 enrolled 1730 patients suspected of having drug-sensitive or drug-resistant tuberculosis at fi ve study sites in South Africa, Peru, Azerbaijan, and India. One direct test on sputum detected 551 (98·2%) of 561 patients with smear-positive tuberculosis and 124 (72·5%) of 171 patients with smear-negative tuberculosis. 27 The test was specifi c in 604 (99·2%) of Series 609 patients without tuberculosis. In patients with smear-negative tuberculosis, processing one, two, or three samples was associated with sensitivities of 72·5%, 85·1%, and 90·2%, respectively. These data formed a substantial part of the evidence base that led to the endorsement of the assay by WHO in 2010.
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A systematic review of studies published up to October, 2011, identifi ed 18 studies containing 10 224 patients. 26 15 reported on diagnosis of pulmonary tuberculosis, and the meta-analysis provided an overall pooled sensitivity of 90·4% (95% CI 89·2-91·4) and a pooled specifi city of 98·4% (98·0-98·7). The pooled sensitivities for sputum smear-negative and smear-positive disease were 75·0% and 98·7%, respectively. Data published after this date have broadly similar fi ndings. A modifi ed G4 version of the cartridge was launched in December, 2011, and independent data on the diagnostic accuracy of this version are needed.
Data about the eff ect of implementation of Xpert MTB/RIF on clinical outcomes of patients investigated for tuberculosis are scarce. FIND did a multicentre assessment of implementation in South Africa, Uganda, Peru, India, Azerbaijan, and the Philippines. 28 In all centres, the GeneXpert machines were located within laboratories at health facilities where smear microscopy was being done. The assay greatly accelerated the time to diagnosis, with a median time of 0 days compared with 1 day for smear microscopy, 16 days with liquid culture, and 20 days with solid culture. 28 For patients with smearnegative tuberculosis, the Xpert MTB/RIF assay reduced the median time to start of treatment from 56 days (IQR 39-81) to 5 days (2-8). Rates of untreated smear-negative culture-positive tuberculosis decreased from 39·3% without the Xpert MTB/RIF assay to 14·7% with the assay. Assay performance for detection of rifampicin resistance was also excellent, with a median time to 29 A positive Xpert MTB/RIF assay result therefore does not imply viability of the organism and thus cannot be used to monitor response to treatment, treatment success, treatment failure, or relapse. Attempts are being made to develop a protocol whereby sputum samples are pretreated to prevent the DNA in non-viable organisms being amplifi ed during PCR. 30 However, even if such an approach proved successful, it would be complex to implement. Alternative approaches being assessed include detection of RNA expression.
Diagnostic accuracy for extrapulmonary tuberculosis
The Xpert MTB/RIF assay was developed, optimised, assessed, and endorsed specifi cally for the detection of pulmonary tuberculosis using sputum. More recently, however, assessments of the assay have extended to various non-respiratory clinical samples from patients with extrapulmonary tuberculosis. Investigation for use in extrapulmonary tuberculosis is far more complex because of the diversity of clinical sample types, diffi culties in obtaining adequate tissue for analyses, the challenge of providing a rigorous reference standard for comparison, and the range of ways to process samples before analysis. Table 1 summarises data from studies of the diagnostic accuracy of the Xpert MTB/RIF assay that included a wide range of diff erent samples from extrapulmonary sites. The reported sensitivity of the assay for extra pulmonary tuberculosis was highly heterogeneous, ranging from 25·0% to 96·6%, but exceeded 50·0% in all but one study (table 1). The heterogeneity between studies might be a result of the diff erences between patient populations, patient selection, type of extra pulmonary tuberculosis, the quality of samples, diff er ences in sample processing, and the diagnostic reference standard used. The median sensitivity of these nine studies was 77·3% (range 25·0-96·6), consistent with a meta-analysis of the few studies published before October, 2011, which reported a pooled sensitivity of 80·4% (95% CI 75·0-85·1). 26 The two largest studies in table 1 reported that the sensitivity of the Xpert MTB/RIF assay was much higher for smear-positive than for smear-negative extrapulmonary tuberculosis samples. 37, 39 Overall, sensitivities exceeded 70% for tissue biopsy samples, fi ne needle aspirates, pus samples, gastric aspirates, and urine.
However, reported sensitivities on small numbers of CSF samples diff ered substantially. 37, 39 Lower sensitivity has been noted when testing pleural, pericardial, peritoneal, and synovial fl uid samples. 33, 39 Increasing evidence from diagnostic accuracy studies might, in the future, open the possibility for international recommendations for use of the assay for diagnosis of extrapulmonary tuberculosis.
Diagnostic accuracy in children
Microbiological confi rmation of tuberculosis is possible only in a small minority of the children treated for the disease, and the time to diagnosis by culture is often prolonged. Table 2 summarises data from fi ve studies on the use of the Xpert MTB/RIF assay to diagnose pulmonary and extrapulmonary tuberculosis in children. Using culture as the reference standard, four of these studies reported that the sensitivity of the Xpert MTB/RIF assay for pulmonary tuberculosis was about two to three times higher than that of smear microscopy when testing induced sputum, nasopharyngeal aspirates, and gastric aspirate lavages. [42] [43] [44] [45] Sensitivity ranged between 65·1% and 75·9% and specifi city was 98·8-100%. Two of the studies reported a high incremental yield (27·8% 42 and 20% 43 ) from testing a second sample. When analysing samples from a wide range of extrapulmonary sites from children, the Xpert MTB/RIF assay generated a substantial diagnostic yield (table 2) . 39 Thus, although most disease in children is still clinically diagnosed, the Xpert MTB/RIF assay increases the proportion with laboratory confi rmation compared with smear microscopy
Country Summary of fi ndings
Nicol et al, 2011 42 South Africa Prospective study of inpatients (n=452) with median age 19 months (maximum 15 years) and suspected TB: from two induced sputum samples, the Xpert MTB/ RIF assay diagnosed 75·9% (44 of 58) of culture-positive cases (specifi city 98·8%) compared with 37·9% using smear microscopy; in smear-negative cases, the incremental yield of the second Xpert MTB/RIF test was 27·8% Rachow et al, 2012 43 Tanzania Prospective study of 164 children aged <14 years (median 5·8 years): of 28 microbiologically confi rmed cases, the Xpert MTB/RIF assay diagnosed 100% (7 of 7) smear-positive cases and 66·6% (14 of 21) smear-negative cases with 100% specifi city; the incremental yields of testing second and third samples were 20% and 16%, respectively
Zar et al 2012 44 South Africa
Prospective study of inpatients (n=535) with median age 19 months (maximum 15 years) and suspected TB: the yield of two Xpert MTB/RIF assay tests on nasopharyngeal aspirates from culture-confi rmed cases was 65% (41 of 63) compared with 33% (21 of 63) by smear microscopy
Bates et al, 2013 45 Zambia Prospective study of inpatients (n=930) with median age 24 months (maximum 15 years) and suspected TB: in culture-positive cases (n=58), the Xpert MTB/RIF assay was more sensitive than smear microscopy when testing sputum samples (90·0% vs 30·0%) or gastric lavage aspirates (68·8% vs 25·0%) and specifi city was 99·3%
Tortoli et al, 2012 39 Italy Study of the diagnosis of extrapulmonary TB in adults and children with a wide range of diff erent sample types (tissue biopsies, pleural fl uid, gastric aspirates, pus, CSF, and urine) that used a composite reference standard of culture, radiology, histology, and treatment response: the sensitivity in samples from children (86·9%) tended to be higher than that in samples from adults (77·6%), possibly as a result of the types of clinical samples in each group
TB=tuberculosis. MTB=Mycobacterium tuberculosis. RIF=rifampicin. 
Diagnostic accuracy in people living with HIV
Diagnosis of HIV-associated tuberculosis is a huge challenge. 47, 48 Table 3 summarises seven studies of patients infected with HIV, comparing the sensitivity of sputum microscopy and the Xpert MTB/RIF assay with culture as the reference standard. The median sensitivity of smear microscopy was 52·8% (range 22·2-68·9) compared with 84·0% (58·3-91·7) with the Xpert MTB/RIF assay. In all seven studies, the sensitivity of the Xpert MTB/RIF assay exceeded that of microscopy with a median increment of 30·0% (range 17·4-37·8). The overall sensitivity of the Xpert MTB/RIF assay for HIV-associated tuberculosis was very heterogeneous (range 58·3-91·7%) and is likely to be a result of patient selection. The lowest sensitivity was in a study in which patients were actively screened for tuberculosis, irre spective of symptoms, and subanalysis showed that the sensitivity was very high in patients who had a cough for 2 weeks or longer. 51 Overall, sensitivities were higher in studies of outpatients with chronic symptoms and higher still in studies of patients admitted to hospital (table 3) . Thus, the sensitivity of the Xpert MTB/RIF assay relates to severity of symptoms, which in turn might refl ect mycobacterial load.
Although the sensitivity of smear microscopy is substantially lower in patients with HIV than in uninfected patients, 47, 48 such an association is unclear for the Xpert MTB/RIF assay. Of the three studies with relevant comparative data 28, 49, 52 (table 3) , two 28,49 studied outpatients and reported that sensitivity was roughly 10% lower in patients with HIV than in those without HIV. However, results of the third study, 52 of inpatients, showed the converse. Importantly, the subset of patients with HIV with culture-positive but Xpert MTB/RIF assay-negative disease have far more favourable prognostic characteristics and a lower risk of death than do those testing positive with the Xpert MTB/RIF assay. 55 Two studies describe the usefulness of the Xpert MTB/RIF assay to diagnose HIV-associated tuberculosis through urine sample testing (table 1) . 40, 41 Despite only small volumes of urine being tested, the yield of HIVassociated tuberculosis was substantial, with positive results in samples from 44·4% of outpatients with culture-positive pulmonary tuberculosis and CD4 cell counts of fewer than 50 cells/μL and 47·8% of inpatients with tuberculosis. Lower CD4 cell counts were strongly associated with higher yield 40 and yield was also in creased 41 This might represent an important alternative diagnostic modality for the sickest patients with HIV-associated tuberculosis, especially those who cannot produce sputum samples. Studies are needed to assess the eff ect of the new diagnostic on diff erent populations, including those in which treatment is frequently started presumptively on the basis of clinical assessment.
Xpert MTB/RIF assay for active pulmonary tuberculosis case fi nding
In addition to screening for tuberculosis before antiretroviral therapy, 51 use of the Xpert MTB/RIF assay for active case fi nding is being explored in other clinical populations. This assay might enable active tuberculosis screening to be done within antenatal clinics in high tuberculosis burden settings, 56 for example, although data are awaited. If this assay was done at point-of-care, screening could be much more readily integrated into the antenatal care pathway. The Xpert MTB/RIF assay has also been used successfully in a small pilot study of active case fi nding in household contacts of smear-positive index cases in Tanzania. 57 In a large tuberculosis prevalence survey in a South African gold mine, 58 the sensitivity was substantially higher than that of smear microscopy, but much lower (62·6%, 95% CI 55·2-69·5) than that of the liquid culture reference standard, which is consistent with the fi ndings of active case fi nding in an antiretroviral treatment clinic. 51 Disadvantages of the Xpert MTB/RIF assay in the prevalence survey were that it tested positive in a subset of patients currently or previously treated for tuberculosis and was also more expensive per test than smear microscopy and liquid culture combined, although this excess cost might be off set by recent cartridge price reductions and by the advantage of test simplicity.
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Rifampicin resistance
Despite the fi rst large-scale multicountry assessment of the Xpert MTB/RIF assay by FIND reporting high specifi city for detection of rifampicin resistance, 27 several subsequent studies have reported cases of confi rmed falsepositive rifampicin resistance detected with the original version of the assay. 50, 51, [59] [60] [61] Although absolute numbers of such cases have been quite small, this drawback is a substantial problem for clinical decision making in settings where the prevalence of rifampicin resistance is low and the positive predictive value for rifampicin resistance is therefore poor. Where resistance is present in more than 15% of isolates, the positive predictive value is estimated to be more than 90%, but where the prevalence is under 5%, the positive predictive value might be less than 70%. 62 Moreover, although the Xpert MTB/RIF assay seems to provide a high sensitivity initial screen for MDR tuberculosis, data from 14 supranational tuberculosis reference laboratories show that 0·5-11·6% of rifampicinresistant strains are sensitive to isoniazid, with marked regional variation. 63 WHO has recom mended that patients with rifampicin-resistant results should receive an MDR tuberculosis treatment regimen pending additional culture-based investigation and DST for fi rst-line and second-line drugs. 62 In addition to false-positive rifampicin resistance results, a few studies reported a high rate of inconclusive results. In 2011, the manufacturers did a root cause analysis of these problems, and software and reagent changes have subsequently been made to the cartridges, including the redesign of probe B. The new software and cartridge combination, called G4, has undergone analytic laboratory assessment, and was launched in December, 2011. 64 Early reports from South Africa suggest that the concordance with the rifampicin resistance results of line-probe assays is improved and that inconclusive results are decreased using the G4 cartridges, 65 but more solid evidence is awaited.
Costs and cost-eff ectiveness
The high cost of this technology (similar to that of liquid culture, but far exceeding that of smear microscopy) is seen as a key hurdle to implementation. 66 ,67 FIND negotiated a discounted pricing structure applicable to 145 high burden and developing countries. 68 A four module GeneXpert platform and linked computer costs about US$17 000 (more than 60% lower than elsewhere). Compared with cartridge costs of roughly $65 in the European Union, discounted costs were initially $18·68 per cartridge when fi rst endorsed by WHO. 69 Costs have since fallen, and with funding from the President's Emergency Plan For AIDS Relief, US Agency for International Devel opment, UNITAID, and the Bill & Melinda Gates Foundation, the cost per cartridge was set at $9·98 from Aug 6, 2012, for the next 10 years. 68 Initial analyses of the use of the Xpert MTB/RIF assay in countries with a high burden of tuberculosis suggest that this technology is likely to be a highly cost-eff ective method of tuberculosis diagnosis, [70] [71] [72] although this will of course be setting specifi c. Cost-eff ectiveness does not denote aff ordability, however, and in the poorest countries of the world with a high tuberculosis burden, the total yearly expenditure per head on health might be little more than $10-20. Moreover, neither the true costs of implementation nor the overall benefi ts are known. In South Africa, for example, the national scale-up of the Xpert MTB/RIF assay is estimated to be associated with a 53-57% increase in the yearly cost of the tuberculosis diagnostic programme. 73 These costs would also vary depending on whether GeneXpert machines were placed only in existing microscopy laboratories or were extended to all facilities providing tuberculosis treatment, which could increase the budget by more than 50%. 74 Moreover, increased overall case detection and diagnosis of MDR tuberculosis are estimated to increase the treatment programme costs by 34-37%. 73 Conversely, the potential benefi ts from reduced morbidity, mortality, and disease Series transmission associated with appropriate delivery of tuberculosis treatment and lower rates of inappropriate therapy have yet to be defi ned. In South Africa, only about half of notifi ed tuberculosis cases are microbiologically confi rmed, and whether implementation of the Xpert MTB/RIF assay will increase the overall number of tuberculosis diagnoses or simply increase the proportion of cases with microbiological confi rmation is unknown. Further cost-eff ectiveness analyses using data generated during scale-up in the fi eld will be essential.
Implementation and scale-up of the Xpert MTB/ RIF assay
WHO policy guidance on the Xpert MTB/RIF assay has been incorporated into national guidelines by a third of reporting countries.
1 Two-thirds of high tuberculosis burden countries and a half of high MDR tuberculosis burden countries have already incorporated the assay into their revised diagnostic policies. Up to the end of June, 2012, 1·1 million test cartridges were procured by 67 (46%) of the 145 countries eligible to purchase them at FIND-negotiated concessional prices.
1,4 Scale-up is expected to be substantially accelerated by the reduction in cartridge costs announced in August, 2012. 68 WHO endorsement of the Xpert MTB/RIF assay has resulted in rapid donor and partner-driven infusions of GeneXpert machines and cartridges into countries. Although this unprecedented support of tuberculosis diagnostic implementation should be encouraged, maxi mising the eff ects and long-term sustainability of the Xpert MTB/RIF assay will probably prove to be dependent on national ministry of health leadership, strategic planning, coordination of technical partners and donors, and continuous monitoring and assessment. Large-scale implementation will invariably need revision of national algorithms, policies, registers, request forms, and moni toring and assessment methods. Thus, ministries of health are encouraged to take a step-wise approach to introduction and scale-up, beginning with the estab lishment of an in-country coordination mechanism, such as an Xpert MTB/RIF assay technical working group or advisory team. Such working groups should include representation from all key stakeholders, including national tuberculosis and AIDS control programmes, national public health laboratories and supranational tuberculosis reference laboratories, imple menting partners, and donors and should be tasked with leading the strategic planning, implementation, and assessment processes. Implementation plans should consider the local epi demiology, available diagnostic services and laboratory systems, and fi rst-line and second-line drug treatment capacity. Moreover, imple mentation should be in line with relevant strategic plans (eg, national tuberculosis and AIDS control programmes and national laboratory strategic plans). Furthermore, implementation should be closely linked to monitoring and assessment of clearly defi ned outcome measures to inform revisions in procedures, policies, and plans.
South Africa has led the way with national implementation of the Xpert MTB/RIF assay. The South African Ministry of Health has recommended replacement of smear microscopy as the initial diagnostic test for tuberculosis. This step is unlikely to be taken by other countries in the region in the foreseeable future because of cost and logistical constraints. As of June, 2012, South Africa accounted for 37% of the modules and 53% of the cartridges procured globally.
1 In March, 2011, the National Department of Health announced the plan to achieve national scale-up over 2-3 years. The South African National Health Laboratory Service launched a pilot programme, placing GeneXpert platforms in 25 smear microscopy centres across the country with throughputs ranging from 16 to more than 400 tests per day. 73 Following this successful pilot, machines are now being placed in all existing smear microscopy laboratories, fully replacing smear microscopy for diagnosis of pulmonary tuber culosis in South Africa. 
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Embedded research studies and monitoring and assessment are likely to yield invaluable data that will increase the understanding of how best to implement this assay.
Challenges associated with implementation
Panel 2 summarises the key strengths and weaknesses of the Xpert MTB/RIF assay and panel 3 summarises the potential benefi ts as well as the challenges of Xpert MTB/ RIF assay implementation for routine use in resourcelimited settings. 66, 75 Increased diagnosis of drug-sensitive tuberculosis and MDR tuberculosis should be matched by expanded capacity to eff ectively treat these cases, including a scale-up in quality MDR tuberculosis treatment facilities and trained staff . Rigorous quality assessment programmes will also be needed, following, for example, a model developed in South Africa that used dried culture spots of inactivated M tuberculosis on fi lter paper. 76 This is essential to ensure that results are accurate.
Despite being relatively simple, implementation of the Xpert MTB/RIF assay in resource-limited settings has needed investments in training of operators and laboratory staff . The computer interface has been more challenging than expected for operators in some countries and additional training has been needed. This issue should be taken into consideration by continuing eff orts aimed at development of nucleic acid amplifi cation-based platforms for implementation in more decentralised facilities. Cartridges have to be stored at 2-28°C, which might be diffi cult in hot climates where trans portation is diffi cult and lengthy and where a cold chain is not available.
A further challenge is the feasibility of deploying the assay at the point-of-care. Centralised location has been associated with failures to link results to patients to inform treatment in a timely manner, under mining outcomes. 77 By contrast, use of the assay at the district and subdistrict levels resulted in a substantial increase in treatment uptake in the FIND implementation study. 28 Location and use within tuberculosis treatment facilities adds further challenges. In South Africa, for example, laboratory placement would need 274 instru ments, whereas location at points of treatment would require 4020 instruments with a 51% increase in cost ($107 million per year). 74 Moreover, results of operational research into point-of-care implementation showed that the turnaround time for sample processing was often more than 2 h and that failure to link results to patients on the same day was an unforeseen diffi culty. 78 A faster assay would be a substantial advantage in this respect. Taking a patient through the whole process of obtaining samples, running the Xpert MTB/RIF assay test, linking results back to the patient, and starting tuberculosis treatment on the same day needed a substantial increase in human resource requirements in the clinic, such that the equivalent of an additional 2·5 staff were needed to manage 16 patients per day suspected of tuberculosis. 78 Use of the assay in the clinic was also associated with increased management responsibilities. Nevertheless, this was off set by increased case detection with same-day treat ment initiation in more than 80% of new cases, a corresponding increase in enthusiasm and morale of clinic staff , and reduced laboratory requirements.
Other advances in tuberculosis diagnostic tests
Further developments in nucleic acid amplifi cation test (NAAT) technology are promising. 4 A simplifi ed manual NAAT using loop-mediated isothermal ampli fi cation with a simple visual colorimetric read-out is being assessed for use in peripheral laboratory facilities in resource-limited settings.
4,79 However, fully automated systems that use isothermal amplifi cation and operate at lower temperatures could potentially be used outside the laboratory environment.
4,80
Hand-held systems the size of a smartphone produce PCR product more rapidly and have much lower power needs than does GeneXpert, permitting battery operation. Identifi cation of resistance mutations to several key drugs with multiplexed assays might greatly reduce the need for follow-on DST. Thus, several fully and administrative responsibilities in clinics • Rapid diagnosis has to be translated into more rapid treatment initiation, which is challenging in some settings • Increased diagnostic capacity should be matched by increases in treatment capacity for drug sensitive and multidrug-resistant tuberculosis • Diagnostic algorithms, notifi cation systems, and methods for monitoring and assessment need to be redefi ned • Restricted operating temperature range • Need for a stable electricity supply • Instruments and associated computers might break down or be stolen • Need for external quality assurance and yearly calibration of instruments • Need for robust supply chains and storage facilities for bulky cartridges with short sh elf-life Series automated assays that compete with the Xpert MTB/RIF assay and that will be more applicable for point-of-care are likely to be developed in the future. 4 However, how the donor assistance that has heavily subsidised the implementation of Xpert MTB/RIF in resource-limited settings will aff ect the development and entry of newer diagnostic assays to the marketplace is not clear. Commercially, funding is not a level playing fi eld. Moreover, the up-front costs of doing fi eld assessment trials needed to gain regulatory approval and WHO endorsement are substantial and might be prohibitive for small com panies. Furthermore, the prospect of the emergence of cheaper rapid tests more applicable at the periphery (community level) poses an interesting dilemma as to whether investment should be made in current more costly technology, or whether it might be better to wait for the next generation of tests to become available.
A promising development is a point-of-care immunochromatographic (dip-stick) assay that detects mycobacterial lipoarabinomannan in urine. [81] [82] [83] The specifi c niche for this assay seems limited to the diagnosis of HIV-associated tuberculosis in patients with advanced immunodefi ciency (CD4 cell counts <200 cells/μL), such as those being screened in antiretroviral treatment clinics or medical inpatients with HIV. 81, [84] [85] [86] Studies from South Africa have reported that in patients with the lowest CD4 cell counts, the assay can potentially diagnose around two-thirds of cases with high specifi city within 30 min. 83 Patients whose tuberculosis is detected by this assay are the subset who are likely to have disseminated tuberculosis, have the highest mortality risk, 87, 88 and are most likely to benefi t from same-day initiation of tuberculosis treatment. More data on standardisation of test production by the manufacturer and on diagnostic accuracy in well conducted studies in diff erent settings are needed, as are studies of clinical eff ect.
Other systems such as breathalysers that detect M tuberculosis-specifi c antigens 89 and so-called electronic noses that detect volatile biomarkers using chemical sensors and pattern recognition systems 90, 91 are being explored. Meanwhile, in the present postgenomics era, the diagnostics developmental pathway should continue to be fuelled by basic research and development to identify biomarkers that can serve as new specifi c targets for diagnostic assays.
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Future prospects for point-of-care diagnosis
The ideal test for tuberculosis will be a true point-of-care assay that enables accurate diagnosis of tuberculosis and detection of drug resistance within the time of a clinic consultation, and one that can be implemented at all levels of the health system for adults and children, with and without HIV. 93 Although the Xpert MTB/RIF assay undoubtedly represents an important breakthrough and step forward towards this ideal, its high relative cost, sophisticated hardware, and constraints for point-of-care use will undoubtedly restrict its implementation. Future advances in molecular diagnostics should build on this success and tackle these remaining challenges. 94 Despite recent developments in nucleic acid amplifi cation-based diagnostics and related technological platforms, the tuberculosis diagnostic pipeline is nevertheless weak and should be strengthened. The need for a better test for paediatric tuberculosis diagnosis is largely unmet because there is no evidence to suggest that the Xpert MTB/RIF assay will have a major eff ect on tuberculosis diagnosis in this group.
Conclusions
The emergence of the Xpert MTB/RIF assay represents a major step forward in tuberculosis diagnostics. Although this assay is not perfect, the advantages off ered in settings with high disease burdens and high rates of drug-resistant and HIV-associated tuberculosis convinced a country such as South Africa to adopt this technology as the initial diagnostic test for pulmonary tuberculosis. More wide-scale implementa tion of the Xpert MTB/RIF assay will provide data on clinical eff ect and programmatic outcomes so that the true costeff ectiveness of the assay can be assessed. Rapid developments in nucleic acid amplifi cation tech nology are fuelling the emergence of further fully automated systems that might be more readily imple mentable at the point of care. However, a rapid, accurate, and aff ordable diagnostic test for tuberculosis that can be easily implemented is urgently needed. Greater investment in the developmental pipeline for tuber culosis diagnostics remains a priority for funders and developers.
